Analyst Reco. Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 20:24:15 09/07/2025 BST			5-day change	1st Jan Change
319.32 ^USD	+0.57%		-3.29%	+35.53%

07-08	Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09:20 AM
07-07	RBC Raises Price Target on Alnylam Pharmaceuticals to $350 From $330, Keeps Outperform Rating	MT

Analyst Reco.

RBC Raises Price Target on Alnylam Pharmaceuticals to $350 From $330, Keeps Outperform Rating	07-07	MT
UBS Adjusts Alnylam Pharmaceuticals Price Target to $349 From $331, Maintains Buy Rating	05-02	MT
BofA Adjusts Price Target on Alnylam Pharmaceuticals to $328 From $325, Keeps Buy Rating	04-17	MT
JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280	03-24	MT
Analyst recommendations: General Mills, Ulta Beauty, Micron Technology, RH…	03-24
BofA Securities Raises Price Target on Alnylam Pharmaceuticals to $325 From $302, Keeps Buy Rating	03-21	MT
RBC Adjusts Price Target on Alnylam Pharmaceuticals to $330 From $310, Maintains Outperform Rating	03-21	MT
Analyst recommendations: Block, Lucid, Celsius, Dun & Bradstreet, Sentinelone...	02-25
Analyst recommendations: Unilever, Glencore, Tesla, XPO, Celanese Corp…	02-24
Analyst recommendations: Nike, Roku, Tesla, XPO, Celanese Corp...	02-24
Analyst recommendations: Alphabet, Lear Corp, Molson Coors, Hasbro, Visa...	02-21
RBC Raises Price Target on Alnylam Pharmaceuticals to $310 From $300, Keeps Outperform Rating	02-14	MT
Mirae Asset Downgrades Alnylam Pharmaceuticals to Hold, Price Target is $236	12-02	MT
Analyst recommendations: Constellation Energy, Dell, HP, Target, J Sainsbury...	11-28
Wolfe Downgrades Alnylam Pharmaceuticals to Underperform From Peer Perform, Price Target at $205	11-12	MT
Analyst recommendations: Airbnb, Estee Lauder, Fortinet, Robinhood, GSK...	11-12
Analyst recommendations: Amazon.com, Mastercard, Bristol-Myers Squibb Company, Uber Technologies, Regeneron Pharmaceuticals...	11-01
Scotiabank Initiates Alnylam Pharmaceuticals at Sector Outperform With $305 Price Target	16/10/24	MT
China Merchants Initiates Alnylam Pharmaceuticals at Buy With $360 Price Target	20/09/24	MT
UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained	19/08/24	MT
Analyst recommendations: Biogen, Cloudflare, Doordash, Moderna, Diageo...	12/08/24
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,089,960, According to a Recent SEC Filing	05/08/24	MT
Chardan Adjusts Alnylam Pharmaceuticals' PT to $300 From $265, Keeps Buy Rating	02/08/24	MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $300 From $265, Keeps Outperform Rating	02/08/24	MT
Analyst recommendations: CrowdStrike, Johnson & Johnson, Netflix, Nvidia, Snap...	23/07/24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Analyst Reco.

Filters